Table 1 Patient characteristics... | American Society of Hematology

Table 1

Patient characteristics

Characteristic	All		Auto-HSCT		Allo-HSCT		P value
Characteristic	No.	%	No.	%	No.	%	P value
Patient number	25		11		14
Age at HSCT (years)
Median	58		57		58		.891
Range	17-67		19-67		17-64
>60 years	9	36	3	27	6	43	.335
Sex, Male	20	80	9	82	11	79	.622
PS, ≥2 at HSCT	2	8	1	9	1	7	.697
Clinical presentation at diagnosis
Skin	22	88	10	91	12	86	.593
Lymph nodes	12	48	4	36	8	57	.265
Peripheral blood	7	28	2	18	5	36	.496
Bone marrow	17	68	8	73	9	64	.496
Induction treatment
NHL-like	11	44	7	64	4	29	.089
ALL-like	10	40	4	36	6	43	.534
AML-like	4	16	0	0	4	29	.079
Disease status at HSCT
CR1	21	84	11	100	10	71	.079
CR2	2	8	0	0	2	14
Refractory	2	8	0	0	2	14
Time from diagnosis to HSCT, months
Median	6		6		5		.496
Range	2-22		2-7		2-22
Year of HSCT, median	2009		2007		2010
Range	2003-2013		2003-2011		2004-2013
Donor type
Related					7	50
Unrelated					7	50
Stem cell source
Peripheral blood					5	36
Bone marrow					8	57
Cord blood					1	7
Myeloablative conditioning					8	57
TBI+CY					4	29
TBI+CY+CA					1	7
Other TBI based					1	7
BU based					2	14
Reduced-intensity conditioning					6	43
Flu+Bu+TBI					2	14
Flu+Mel+TBI					1	7
Flu+Bu					1	7
Flu+Mel+TBI					1	7
Other Flu based					1	7
High-dose regimen for auto-HSCT
MCEC based			4	36
MEAM based			2	18
TBI bases			4	36
LEED			1	9

Characteristic	All		Auto-HSCT		Allo-HSCT		P value
Characteristic	No.	%	No.	%	No.	%	P value
Patient number	25		11		14
Age at HSCT (years)
Median	58		57		58		.891
Range	17-67		19-67		17-64
>60 years	9	36	3	27	6	43	.335
Sex, Male	20	80	9	82	11	79	.622
PS, ≥2 at HSCT	2	8	1	9	1	7	.697
Clinical presentation at diagnosis
Skin	22	88	10	91	12	86	.593
Lymph nodes	12	48	4	36	8	57	.265
Peripheral blood	7	28	2	18	5	36	.496
Bone marrow	17	68	8	73	9	64	.496
Induction treatment
NHL-like	11	44	7	64	4	29	.089
ALL-like	10	40	4	36	6	43	.534
AML-like	4	16	0	0	4	29	.079
Disease status at HSCT
CR1	21	84	11	100	10	71	.079
CR2	2	8	0	0	2	14
Refractory	2	8	0	0	2	14
Time from diagnosis to HSCT, months
Median	6		6		5		.496
Range	2-22		2-7		2-22
Year of HSCT, median	2009		2007		2010
Range	2003-2013		2003-2011		2004-2013
Donor type
Related					7	50
Unrelated					7	50
Stem cell source
Peripheral blood					5	36
Bone marrow					8	57
Cord blood					1	7
Myeloablative conditioning					8	57
TBI+CY					4	29
TBI+CY+CA					1	7
Other TBI based					1	7
BU based					2	14
Reduced-intensity conditioning					6	43
Flu+Bu+TBI					2	14
Flu+Mel+TBI					1	7
Flu+Bu					1	7
Flu+Mel+TBI					1	7
Other Flu based					1	7
High-dose regimen for auto-HSCT
MCEC based			4	36
MEAM based			2	18
TBI bases			4	36
LEED			1	9

BU, busulfan; CA, cytarbine; CY, cyclophosphamide; Flu, fludarabine; LEED, cyclophosphamide, etoposide, melphalan, and dexamethasone; MCEC, ranimustine, carboplatin, etoposide, and cyclophosphamide; MEAM, ranimustine, etoposide, cytarbine, and melphalan; Mel, melphalan; TBI, total body irradiation.

View Large

This Feature Is Available To Subscribers Only